Moreover, the analysis of anti-tumor drugs suggested that the AML patients exhibiting high levels of PSMD11/14 expression may benefit from utilizing mTOR inhibitors or proteasome inhibitors. The gene discussed is PSMD11; the disease is neoplasm.